Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

230 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-12

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

NCT04049331

Hypogonadism, Male Fatigue Syndrome, Chronic

RECRUITING PHASE2

Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients

NCT00965341

Advanced Cancer

COMPLETED PHASE3

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

NCT03716739

Prostate Cancer

COMPLETED PHASE2

Study of The Effects of Testosterone in Frail Elderly Men

NCT00190060

Frailty Sarcopenia

COMPLETED PHASE4

Short-term Testosterone Replacement in Testicular Cancer Survivors

NCT03339635

Testicular Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall objective is to conduct a double-blind, randomized, placebo-controlled, parallel group trial to determine the efficacy of 6 months of physiological testosterone replacement therapy in improving cancer related fatigue, sexual dysfunction, and body composition and muscle function in men 55 years and older with solid or hematologic (blood) cancers, who report fatigue and have testosterone deficiency. There will be 5 study visits: 1) Screening, 2) Baseline, 3) 2-Week Dose Adjustment Visit, 4) Three-month visit (Week 12), and 5) Six-month visit. Testosterone or placebo gels will be applied by eligible trial participants at home; participants will be trained on gel application procedures by research personnel.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypogonadism, Male Cancer Fatigue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomized, double-blind, placebo-controlled, parallel group, trial of daily transdermal testosterone gel or placebo gel for 6-months

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

testosterone 1.62% gel

Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.

Group Type EXPERIMENTAL

testosterone 1.62% gel

Intervention Type DRUG

The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months

placebo gel

The placebo gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.

Group Type PLACEBO_COMPARATOR

placebo gel

Intervention Type OTHER

The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

testosterone 1.62% gel

The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months

Intervention Type DRUG

placebo gel

The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men with active solid or hematologic (blood) cancers who have received or are receiving chemo- and/or radiation therapy. Patients who have no evidence of disease (NED) for 60 months or less, which means that they are \<60 months from their last treatment (chemotherapy and/or radiation therapy) will be included.
* Age: 55 years and older
* Life expectancy of at least 6 months.
* Serum testosterone, measured by mass spectrometry (gold standard method), of \<348 ng/dl and/or free testosterone \<70 pg/ml. The lower limits of the normal range for total testosterone in healthy men is 348 ng/dL and the lower limits of free testosterone is \<70 pg/ml in the Framingham Heart Study sample. As sex hormone binding globulin levels may be elevated in some men with cancer (resulting in elevation in total testosterone level), some of these symptomatic men may still be hypogonadal despite having total testosterone above this cut-off limit, but their free testosterone levels may still be below the lower limit of normal. Thus, men with free testosterone \<70 pg/mL will be included.
* Fatigue. Fatigue was selected as it is a highly prevalent symptom in cancer patients. Fatigue will be defined as a score on FACIT-Fatigue subscale of \<40, which best divides cancer patients from the general population with accuracy.
* Ability and willingness to provide informed consent

Exclusion Criteria

* Men with current or prior history of prostate, breast, testicular, or adrenal cancers.
* Use of anabolic agents (testosterone, DHEA, growth hormone) within the past 6 months
* Hematocrit \>48%, serum creatinine \>2.5 mg/dL
* PSA \>4 ng/ml; nodule or induration on digital rectal exam
* Severe untreated sleep apnea
* Uncontrolled congestive heart failure
* Myocardial infarction, acute coronary syndrome, revascularization surgery, stroke or thromboembolism (of any etiology) within 6 months
* Known history of thrombophilia due to a genetic mutation (e.g. Factor V Leiden)
* Previous stroke with residual cognitive or functional deficits
* Inability to provide informed consent; MMSE score \<24
* Poorly controlled diabetes as defined by hemoglobin A1c \>10.0%
* Body mass index (BMI) \>40 kg/m2
* Bipolar disorder or schizophrenia

Minimum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No